Literature DB >> 27123272

An 80-gene set to predict response to preoperative chemoradiotherapy for rectal cancer by principle component analysis.

Shinichiro Empuku1, Kentaro Nakajima1, Tomonori Akagi1, Kunihiko Kaneko2, Naoki Hijiya3, Tsuyoshi Etoh1, Norio Shiraishi4, Masatsugu Moriyama3, Masafumi Inomata1.   

Abstract

Preoperative chemoradiotherapy (CRT) for locally advanced rectal cancer not only improves the postoperative local control rate, but also induces downstaging. However, it has not been established how to individually select patients who receive effective preoperative CRT. The aim of this study was to identify a predictor of response to preoperative CRT for locally advanced rectal cancer. This study is additional to our multicenter phase II study evaluating the safety and efficacy of preoperative CRT using oral fluorouracil (UMIN ID: 03396). From April, 2009 to August, 2011, 26 biopsy specimens obtained prior to CRT were analyzed by cyclopedic microarray analysis. Response to CRT was evaluated according to a histological grading system using surgically resected specimens. To decide on the number of genes for dividing into responder and non-responder groups, we statistically analyzed the data using a dimension reduction method, a principle component analysis. Of the 26 cases, 11 were responders and 15 non-responders. No significant difference was found in clinical background data between the two groups. We determined that the optimal number of genes for the prediction of response was 80 of 40,000 and the functions of these genes were analyzed. When comparing non-responders with responders, genes expressed at a high level functioned in alternative splicing, whereas those expressed at a low level functioned in the septin complex. Thus, an 80-gene expression set that predicts response to preoperative CRT for locally advanced rectal cancer was identified using a novel statistical method.

Entities:  

Keywords:  histological response; microarray analysis; preoperative chemoradiotherapy; principle component analysis; rectal cancer

Year:  2016        PMID: 27123272      PMCID: PMC4840568          DOI: 10.3892/mco.2016.806

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  27 in total

1.  Minimum information about a microarray experiment (MIAME)-toward standards for microarray data.

Authors:  A Brazma; P Hingamp; J Quackenbush; G Sherlock; P Spellman; C Stoeckert; J Aach; W Ansorge; C A Ball; H C Causton; T Gaasterland; P Glenisson; F C Holstege; I F Kim; V Markowitz; J C Matese; H Parkinson; A Robinson; U Sarkans; S Schulze-Kremer; J Stewart; R Taylor; J Vilo; M Vingron
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

2.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

3.  A gene expression signature for chemoradiosensitivity of colorectal cancer cells.

Authors:  Melanie Spitzner; Georg Emons; Frank Kramer; Jochen Gaedcke; Margret Rave-Fränk; Jens-Gerd Scharf; Peter Burfeind; Heinz Becker; Tim Beissbarth; B Michael Ghadimi; Thomas Ried; Marian Grade
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-11-15       Impact factor: 7.038

Review 4.  Septin roles in tumorigenesis.

Authors:  Diana Connolly; Ines Abdesselam; Pascal Verdier-Pinard; Cristina Montagna
Journal:  Biol Chem       Date:  2011-07-11       Impact factor: 3.915

5.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

Review 6.  Alternative transcription and alternative splicing in cancer.

Authors:  Sharmistha Pal; Ravi Gupta; Ramana V Davuluri
Journal:  Pharmacol Ther       Date:  2012-08-14       Impact factor: 12.310

Review 7.  Septins: the fourth component of the cytoskeleton.

Authors:  Serge Mostowy; Pascale Cossart
Journal:  Nat Rev Mol Cell Biol       Date:  2012-02-08       Impact factor: 94.444

Review 8.  Role of phosphoproteomics in the development of personalized cancer therapies.

Authors:  Pedro R Cutillas
Journal:  Proteomics Clin Appl       Date:  2015-02-27       Impact factor: 3.494

9.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nucleic Acids Res       Date:  2008-11-25       Impact factor: 16.971

10.  Immunohistochemical analysis of organic anion transporter 2 and reduced folate carrier 1 in colorectal cancer: Significance as a predictor of response to oral uracil/ftorafur plus leucovorin chemotherapy.

Authors:  Satoshi Nishino; Ayumi Itoh; Hiroshi Matsuoka; Kotaro Maeda; Shingo Kamoshida
Journal:  Mol Clin Oncol       Date:  2013-04-15
View more
  2 in total

1.  A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer.

Authors:  Hajime Fujishima; Shoichi Fumoto; Tomotaka Shibata; Kohei Nishiki; Yoshiyuki Tsukamoto; Tsuyoshi Etoh; Masatsugu Moriyama; Norio Shiraishi; Masafumi Inomata
Journal:  PLoS One       Date:  2017-11-14       Impact factor: 3.240

2.  Gene-expression profiles of pretreatment biopsies predict complete response of rectal cancer patients to preoperative chemoradiotherapy.

Authors:  Georg Emons; Noam Auslander; Peter Jo; Thomas Ried; Jochen Gaedcke; Julia Kitz; Azadeh Azizian; Yue Hu; Clemens F Hess; Claus Roedel; Ulrich Sax; Gabriela Salinas; Philipp Stroebel; Frank Kramer; Tim Beissbarth; Marian Grade; Michael Ghadimi; Eytan Ruppin
Journal:  Br J Cancer       Date:  2022-05-21       Impact factor: 9.075

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.